Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Strong-Third-Quarter-2022-Results-Maintains-Full-Year-2022-Financial-Guidance/default.aspx
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2022-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Host-Third-Quarter-2022-Investor-Update-Call/default.aspx
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Positive-Topline-Data-from-Phase-III-Trial-of-LINZESS-linaclotide-in-Pediatric-Patients-Aged-6-17-with-Functional-Constipation/default.aspx
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Positive-Topline-Data-from-Phase-III-Trial-of-LINZESS-linaclotide-in-Pediatric-Patients-Aged-6-17-with-Functional-Constipation/default.aspx
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Present-at-the-2022-Wells-Fargo-Healthcare-Conference/default.aspx
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Present-at-the-2022-Wells-Fargo-Healthcare-Conference/default.aspx
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2022-Results-Maintains-Full-Year-Guidance-Due-to-Continued-Strength-of-LINZESS-Prescription-Demand/default.aspx
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-Reports-Second-Quarter-2022-Results-Maintains-Full-Year-Guidance-Due-to-Continued-Strength-of-LINZESS-Prescription-Demand/default.aspx
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
https://investor.ironwoodpharma.com/press-releases/press-release-details/2022/Ironwood-Pharmaceuticals-to-Host-Second-Quarter-2022-Investor-Update-Call/default.aspx